Research programme: anticancer therapeutics - Cancer Research UK/Novartis
Latest Information Update: 28 Jun 2021
At a glance
- Originator Cancer Research UK
- Developer Cancer Research UK; Novartis
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer